Experimental cell research最新文献

{"title":"Phosphofructokinase in glycolysis: Bridging enzymology and cell biology","authors":"Ashesh Sharma ,&nbsp;Songon An","doi":"10.1016/j.yexcr.2026.114887","DOIUrl":"10.1016/j.yexcr.2026.114887","url":null,"abstract":"<div><div>ATP-dependent phosphofructokinase (PFK) catalyzes a key committed step in glycolysis. Also called the “gatekeeper” of glycolysis, PFKs catalyze an irreversible phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate. While eukaryotic PFKs are more than double the size of prokaryotic PFKs, the overall structure and mechanism of PFKs are largely conserved from prokaryotes to eukaryotes. Usually tetrameric to be active, PFKs are also found to form higher-order structures, such as octamers in yeasts and multimeric filaments in mammals. Due to their central role in glycolysis, the enzymatic activity of PFKs is highly regulated by a myriad of allosteric effectors, post-translational modifications, and various signaling pathways. Such complex regulatory networks of PFKs often result from and/or result in a variety of protein-protein interactions, thus providing the molecular basis of dynamic association and dissociation of PFKs into multienzyme metabolic assemblies (i.e., metabolons) in cells. The concept of metabolon has now become an organizational principle for a cell to regulate the function of PFKs and thus govern glycolysis. Therefore, this article aims to integrate current knowledge in PFK enzymology and cell biology to provide a molecular and cellular framework for repositioning this century-old drug target for innovative therapeutic applications.</div></div>","PeriodicalId":12227,"journal":{"name":"Experimental cell research","volume":"456 1","pages":"Article 114887"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MiR-181c-5p-SIRT1 axis-driven Pink1/Parkin-mediated mitophagy prevents ferroptosis and vascular calcification in chronic kidney disease","authors":"Ruman Chen ,&nbsp;Jiqing He ,&nbsp;Na An,&nbsp;Mingzhi Xu,&nbsp;Liheng Wang,&nbsp;Yafei Bai","doi":"10.1016/j.yexcr.2025.114875","DOIUrl":"10.1016/j.yexcr.2025.114875","url":null,"abstract":"<div><h3>Background</h3><div>Vascular calcification (VC) is a severe cardiovascular complication of chronic kidney disease (CKD), driven by vascular smooth muscle cell (VSMC) osteogenic trans-differentiation and exacerbated by oxidative stress and cellular dysfunction. Despite its clinical relevance, the molecular mechanisms underlying CKD-associated VC remain incompletely understood. This study investigates the role of Sirtuin 1 (SIRT1) in modulating VC through ferroptosis inhibition and mitophagy activation and examines whether microRNA-181c-5p (miR-181c-5p) contributes to SIRT1 dysregulation in this context.</div></div><div><h3>Methods</h3><div>A CKD-associated VC model was induced in rats by 5/6 nephrectomy followed by high calcium/phosphate and calcitriol loading, and an <em>in vitro</em> calcification model was established in primary rat VSMCs. SIRT1 was manipulated using AAV9-mediated overexpression <em>in vivo</em> and plasmid overexpression or inhibition <em>in vitro</em>. Upstream regulation of SIRT1 by miR-181c-5p was predicted bioinformatically and validated by RNA pull-down and dual-luciferase assays. Ferroptosis was assessed by redox and Fe²⁺ indices, and mitophagy by Pink1/Parkin, LC3-II and p62 expression. Rescue experiments employed erastin, Mdivi-1 and Parkin knockdown.</div></div><div><h3>Results</h3><div>SIRT1 expression was markedly reduced in calcified aortic tissues and VSMCs. SIRT1 overexpression suppressed VC by reducing calcium deposition, downregulating osteogenic markers, and increasing fetuin-A levels. SIRT1 also suppressed ferroptosis by restoring the GSH/GPX4/SLC7A11 axis and limiting ROS and lipid peroxidation, whereas erastin abolished these effects. Mechanistically, miR-181c-5p was found to directly target SIRT1 and promote VSMC calcification by repressing SIRT1. Moreover, SIRT1 promoted mitophagy via the Pink1/Parkin pathway activation. Furthermore, inhibition of mitophagy reversed the anti-ferroptotic effects of SIRT1, confirming their functional interplay.</div></div><div><h3>Conclusions</h3><div>SIRT1, negatively regulated by miR-181c-5p, mitigates CKD-associated VC by suppressing ferroptosis and activating Pink1/Parkin-dependent mitophagy in VSMCs, highlighting a potential therapeutic axis for vascular protection in CKD.</div></div><div><h3>Clinical trial registration number</h3><div>Not applicable.</div></div>","PeriodicalId":12227,"journal":{"name":"Experimental cell research","volume":"456 1","pages":"Article 114875"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetic mechanism of LncRNA KCNQ1OT1 in high-glucose-induced podocyte injury via m6A methylation modification","authors":"Yikai Hou ,&nbsp;Danli Wang ,&nbsp;Lijun Liu ,&nbsp;Jiakun Tian ,&nbsp;Min Zhi ,&nbsp;Yongbing Shi","doi":"10.1016/j.yexcr.2026.114897","DOIUrl":"10.1016/j.yexcr.2026.114897","url":null,"abstract":"<div><div>Podocyte injury is a hallmark of diabetic nephropathy associated with proteinuria and renal dysfunction. This study elucidated the role of long non-coding RNA KCNQ1 overlapping transcript 1 (LncRNA KCNQ1OT1) in high-glucose (HG)-induced podocyte injury. In HG-treated podocytes, KCNQ1OT1, WTAP, and MAPK6 were quantified. After KCNQ1OT1 interference, cell viability, apoptosis, inflammation, and oxidative stress were measured. Subcellular localization of KCNQ1OT1 was determined by nuclear-cytoplasmic fractionation and RNA FISH. Binding of MLL1 to KCNQ1OT1 was validated via RNA pull-down and RIP. MLL1/H3K4me3 enrichment on the WTAP promoter was detected by ChIP. m6A levels of MAPK6 were measured by MeRIP. Binding of IGF2BP1 to MAPK6 was confirmed via RIP. Rescue experiments explored the WTAP/MAPK6 axis in podocyte injury. HG treatment upregulated KCNQ1OT1, WTAP, and MAPK6 in podocytes. KCNQ1OT1 knockdown enhanced cell proliferation, reduced apoptosis, and attenuated inflammation and oxidative stress. Mechanistically, nuclear-localized KCNQ1OT1 recruited MLL1 to the WTAP promoter, enhancing H3K4me3 modification and WTAP activation. WTAP promoted m6A methylation of MAPK6 mRNA, which was stabilized by IGF2BP1. Overexpression of WTAP or MAPK6 abrogated the protective effects of KCNQ1OT1 knockdown on podocytes injury. In conclusions, KCNQ1OT1 exacerbates HG-induced podocyte injury by upregulating the WTAP/MAPK6 axis in an m6A-dependent manner.</div></div>","PeriodicalId":12227,"journal":{"name":"Experimental cell research","volume":"456 1","pages":"Article 114897"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fetuin B drives metabolism-associated steatohepatitis by promoting hepatocyte pyroptosis via NLRP3/GSDMD pathway","authors":"Shi Chen ,&nbsp;Yue Wang ,&nbsp;Jingwen Gao ,&nbsp;Jiaxi Lin ,&nbsp;Lu Liu ,&nbsp;Shiqi Zhu ,&nbsp;Lihe Liu ,&nbsp;Chunfang Xu ,&nbsp;Xiaolin Liu ,&nbsp;Manhui Zhu ,&nbsp;Jinzhou Zhu","doi":"10.1016/j.yexcr.2026.114886","DOIUrl":"10.1016/j.yexcr.2026.114886","url":null,"abstract":"<div><div>Hepatocyte pyroptosis critically contributes to metabolism-associated fatty liver disease (MAFLD) progression. Fetuin-B (FETUB), a hepatocytokine, promotes pyroptosis by downregulating adiponectin receptor 1 (AdipoR1), thereby activating the NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome/GSDMD pathway. This study investigated the role of FETUB in metabolic dysfunction-associated steatohepatitis (MASH) and the therapeutic efficacy of FETUB inhibition. In primary mouse hepatocytes, free fatty acid (FFA) stimulation upregulated FETUB transcription, expression, and secretion, which suppressed membrane AdipoR1 and triggered NLRP3/GSDMD-mediated pyroptosis, exacerbating steatosis. In high-fat diet (HFD)-induced MASH mice, hepatic FETUB expression increased concordantly with AdipoR1 downregulation. FETUB blockade ameliorated hepatic steatosis, inflammation, ballooning, and fibrosis by disrupting this pathway. These findings establish FETUB as a key regulator of NLRP3/GSDMD-driven pyroptosis in MASH and identify it as a promising therapeutic target.</div></div>","PeriodicalId":12227,"journal":{"name":"Experimental cell research","volume":"456 1","pages":"Article 114886"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145915416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PLA2R1-mediated ERK-Dependent ferroptosis: A key pathogenic mechanism in epileptic neuronal injury","authors":"Hong Chen ,&nbsp;Guohang Wu ,&nbsp;Qiannan Song","doi":"10.1016/j.yexcr.2026.114904","DOIUrl":"10.1016/j.yexcr.2026.114904","url":null,"abstract":"<div><h3>Background</h3><div>Phospholipase A2 receptor 1 (PLA2R1) plays a regulatory role in pathological processes, but its mechanism in epileptic neuronal injury remains unclear. This study aimed to elucidate how PLA2R1 promotes epileptic neuronal injury through ERK-dependent ferroptosis.</div></div><div><h3>Methods</h3><div>A kainic acid-induced epilepsy mouse model was employed. PLA2R1 expression was detected using qRT-PCR, Western blot, and immunofluorescence. PLA2R1 knockdown and overexpression vectors were constructed to observe effects on seizure severity and neuronal injury. Ferroptosis indicators (GPX4, ACSL4, PTGS2, MDA, ROS, GSH) were analyzed. HT22 cells were used for in vitro validation with glutamate and Erastin-induced ferroptosis. ERK pathway involvement was verified using inhibitor SCH772984.</div></div><div><h3>Results</h3><div>PLA2R1 was upregulated in epileptic tissues. PLA2R1 knockdown prolonged seizure latency, reduced seizure intensity, decreased neuronal injury, and inhibited ERK activation. It upregulated GPX4 and GSH while downregulating ACSL4, PTGS2, MDA, and ROS. PLA2R1 overexpression exacerbated ferroptosis-related neuronal injury. In vitro experiments confirmed that ferroptosis inducers upregulated PLA2R1, while knockdown improved neuronal survival. ERK inhibitor SCH772984 reversed PLA2R1 overexpression-induced neuronal injury.</div></div><div><h3>Conclusion</h3><div>This study identified the PLA2R1-MEK-ERK-ferroptosis signaling axis, suggesting that PLA2R1 contributes to neuronal ferroptosis through ERK pathway activation in epilepsy. PLA2R1's druggability and ERK inhibitors' clinical safety provide foundation for therapeutic translation.</div></div>","PeriodicalId":12227,"journal":{"name":"Experimental cell research","volume":"456 1","pages":"Article 114904"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"S-nitrosylated COX-2 is a microenvironment-regulated breast cancer cell biomarker of mesenchymal phenotypes","authors":"Reuben J. Hoffmann ,&nbsp;AeSoon Bensen ,&nbsp;Mark Dane,&nbsp;Jane Arterberry,&nbsp;Rebecca Smith,&nbsp;James Korkola,&nbsp;Pepper Schedin","doi":"10.1016/j.yexcr.2026.114888","DOIUrl":"10.1016/j.yexcr.2026.114888","url":null,"abstract":"<div><div>COX-2, an inducible enzyme key to production of inflammatory prostaglandins, has tumor cell-intrinsic oncogenic activity. Previously, we reported Cys-526-nitrosylated COX-2 (SNO-COX-2) associates with breast cancer progression and poor-prognostic young onset breast cancer. Here, using a 3D culture model of early-stage human breast cancer (MCF10DCIS cells), we report SNO-COX-2, but not non-nitrosylated COX-2, closely associated with mesenchymal cell phenotypes induced by fibrillar Col1. Inhibition of nitric oxide synthase (NOS) activity did not reduce SNO-COX-2 levels, suggesting alternative nitrosylation mechanisms. In 3D MCF10DCIS culture, mesenchymal phenotypes and SNO-COX-2 protein induced by Col1 did not associate with transcription of classic epithelial-to-mesenchymal transition (EMT) markers nor common cancer signaling pathways. Conversely, TGFβ-1 strongly induced EMT- and cancer signaling-related transcripts but was insufficient to increase SNO-COX-2 protein or mesenchymal phenotypes. These data suggest the mesenchymal phenotype and SNO-COX-2 expression in MCF10DCIS are driven by a non-transcriptional mechanism dependent on Col1. We tested 300 additional microenvironmental conditions and find SNO-COX-2 expression is driven by inflammatory, wound-resolving, and cancer-associated TME factors, including TNC, SPP1, decorin, Col1, Col3, INF-γ, and IL-4/13, with specific extracellular matrix-ligand combinations driving both high and low SNO-COX-2 expression. In sum, these observations show that in MCF10DCIS cells, SNO-COX-2 associates with mesenchymal phenotypes more strongly than non-nitrosylated COX-2; expression of classic EMT transcripts is neither sufficient nor necessary for acquisition of mesenchymal phenotypes; and expression of SNO-COX-2 is highly microenvironment-dependent. Future studies evaluating SNO-COX-2 as a biomarker for early-stage breast cancer with increased risk for progression, and its regulation, are warranted.</div></div>","PeriodicalId":12227,"journal":{"name":"Experimental cell research","volume":"456 1","pages":"Article 114888"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GNA15 as a potential prognostic and immunological biomarker in ccRCC based on bioinformatics analysis and experimental verification","authors":"Xiumin Xu ,&nbsp;Zeping Zuo ,&nbsp;Jinhai Zhu ,&nbsp;Jun Wu ,&nbsp;Tao Zhang","doi":"10.1016/j.yexcr.2025.114874","DOIUrl":"10.1016/j.yexcr.2025.114874","url":null,"abstract":"<div><div>As the most common and aggressive subtype of renal cancer, clear cell renal cell carcinoma (ccRCC) often shows poor responsiveness to current therapeutic strategies. Although GNA15, a G protein alpha subunit, has been associated with the progression of multiple tumor types, its functional significance in ccRCC remains largely undefined. Public datasets were used to profile GNA15 expression across cancers, and its links to prognosis, genomic diversity, stemness, and immune infiltration were analyzed with multiple computational tools. In ccRCC, transcriptomic and protein expression levels were validated using immunofluorescence and western blotting. Functional assays, including colony formation, transwell migration, tumor spheroid formation, and GSEA, were used to investigate the biological role of GNA15. The effects of GNA15 knockdown were assessed in renal cancer cell lines. GNA15 was aberrantly upregulated in multiple cancers and significantly elevated in ccRCC tissues and cell lines. High GNA15 expression correlated with poor overall survival and advanced clinical stage. It was also positively associated with tumor heterogeneity, stemness, and immunosuppressive microenvironment characteristics, particularly M2 macrophage and neutrophil infiltration. GSEA identified enrichment in oncogenic pathways, including JAK-STAT, Wnt, and Notch signaling. In vitro knockdown of GNA15 reduced tumor cell proliferation, migration, spheroid formation, and expression of stemness markers and PD-L1. Our results highlight GNA15 as a novel oncogenic and immune-related contributor to ccRCC progression, supporting its potential as a prognostic biomarker and therapeutic target.</div></div>","PeriodicalId":12227,"journal":{"name":"Experimental cell research","volume":"455 2","pages":"Article 114874"},"PeriodicalIF":3.5,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145843526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “ISG15 promotes esophageal squamous cell carcinoma tumorigenesis via c-MET/Fyn/β-catenin signaling pathway” [Exp. Cell Res. 367 (2018) 47–55]","authors":"Hongyu Yuan ,&nbsp;Wei Zhou ,&nbsp;Yang Yang ,&nbsp;Liyan Xue ,&nbsp;Linxiu Liu ,&nbsp;Yongmei Song","doi":"10.1016/j.yexcr.2025.114873","DOIUrl":"10.1016/j.yexcr.2025.114873","url":null,"abstract":"","PeriodicalId":12227,"journal":{"name":"Experimental cell research","volume":"455 2","pages":"Article 114873"},"PeriodicalIF":3.5,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145896386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor cell exosome circ-0023919 promotes EMT through the miR-197-5p/ICAM5 axis and enhances the drug resistance of colorectal cancer to 5-fu","authors":"Jingjing Zhang,&nbsp;Yuanxiang Wu,&nbsp;Yaping Wang,&nbsp;Huihui Zeng","doi":"10.1016/j.yexcr.2025.114866","DOIUrl":"10.1016/j.yexcr.2025.114866","url":null,"abstract":"<div><div>5-Fluorouracil (5-Fu) is a cornerstone chemotherapeutic agent in the treatment of colorectal cancer (CRC). However, its clinical efficacy is frequently hampered by the development of drug resistance, which remains a major obstacle to successful treatment. The aim of this study is to gain a comprehensive understanding of the role and mechanism of the tumor cell-derived exosomal circ-0023919 in 5-Fu resistance. High-throughput microarray technology was employed to identify differentially expressed circRNAs in 5-Fu resistance CRC cells and their derived exosomes. A CRC/5-Fu drug-resistant cell line was successfully established using the drug gradient induction method, and its resistance index was subsequently determined. We employed transmission electron microscopy, nanoparticle tracking analysis (NTA) and Western blot to characterize exosomes by detecting the exosomal markers CD63 and TSG101. The circular structure, stability, and subcellular localization of circ-0023919 were confirmed using a combination of approaches, including actinomycin D treatment, RNase R digestion, specific primer PCR amplification, Sanger sequencing and FISH. Furthermore, we systematically evaluated the regulatory role of circ-0023919 in multiple biological functions of CRC cells by assessing cell proliferation, migration, invasion, drug resistance, stemness and EMT-related markers. Our findings demonstrate that circ-0023919 promotes the migration and invasion of CRC/5-Fu cells both in vitro and in vivo, while also enhancing resistance to 5-Fu chemotherapy. Mechanistically, circ-0023919 acts as a molecular sponge for miR-197-5p, thereby upregulating the expression of ICAM5. In this scientific study, circ-0023919 is shown to enhance the resistance of CRC cells to 5-Fu by promoting EMT. Thus, circ-0023919 is considered a potential therapeutic target for CRC treatment.</div></div>","PeriodicalId":12227,"journal":{"name":"Experimental cell research","volume":"455 2","pages":"Article 114866"},"PeriodicalIF":3.5,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145762535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FBXL6 drives tumorigenesis in lung adenocarcinoma through ubiquitination and proteasomal degradation of CDKN1C","authors":"Guanzhong Dong,&nbsp;Ning Zhang,&nbsp;Dong Yang,&nbsp;Zibo Zhu,&nbsp;Yi He","doi":"10.1016/j.yexcr.2025.114872","DOIUrl":"10.1016/j.yexcr.2025.114872","url":null,"abstract":"<div><div>Lung adenocarcinoma (LUAD) is a highly prevalent and lethal malignancy. Although F-box and leucine-rich repeat protein 6 (FBXL6), an E3 ubiquitin ligase, has been implicated in tumor progression across certain cancers, its functional role in LUAD remains unclear. In this study, we investigated the oncogenic potential of FBXL6 in LUAD pathogenesis. Bioinformatics analysis of GEO, TCGA, and TNM datasets revealed significant upregulation of FBXL6 in LUAD tissues. Functional studies using FBXL6-knockdown (via shRNA in PC-9 cells) and FBXL6-overexpressing (via plasmid transfection in A549 cells) demonstrated that FBXL6 depletion suppressed cell proliferation, migration, and invasion, whereas its overexpression reversed these effects. In vivo experiments further confirmed that FBXL6 knockdown in PC-9 cells inhibited tumor growth and liver metastasis in BALB/c nude mice following subcutaneous or tail vein injection. Mechanistically, FBXL6 was found to physically interact with cyclin-dependent kinase inhibitor 1C (CDKN1C/p57Kip2) and promote its polyubiquitination and proteasomal degradation, thereby destabilizing this tumor suppressor. Rescue assays validated that CDKN1C mediates the pro-tumorigenic effects of FBXL6 on LUAD cell proliferation and metastasis. Collectively, our findings reveal that FBXL6 drives LUAD progression by ubiquitinating and degrading CDKN1C, highlighting its potential as a therapeutic target for LUAD.</div></div>","PeriodicalId":12227,"journal":{"name":"Experimental cell research","volume":"455 2","pages":"Article 114872"},"PeriodicalIF":3.5,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}